Heterocyclic analogues of ursolic acid as Cdk1/Cyclin B1 binders: design, synthesis, cytotoxic evaluation, and molecular docking study

Authors: Manga, Bandari; Venkateswara Rao, Banoth; Adla, Deepthi; Mutheneni, Srinivasa Rao; Swain, Sonam; Jain, Nishant; Ramalingam, Vaikundamoorthy; Babu, K Suresh

Source journal: Natural product research (2026-11-20)

DOI: 10.1080/14786419.2026.2765378

Abstract

In the pursuit of novel anticancer agents derived from natural sources, thirteen known compounds (1-13) were isolated from leaves of Gardenia turgida, Roxb and ursolic acid (4) was identified as the major constituent. To further improve cytotoxic activity and investigate structure-activity relationships, a series of ursolic acid derivatives 4a-4b, 4c-4d, and 4e-4i containing various heterocyclic moieties was synthesised. The anticancer potential of both the natural isolates and their synthetic derivatives was evaluated in vitro against a panel of cancer cell lines. Among them, compounds 4b and 4g exhibited notable anti-proliferative activity against fibrosarcoma cells. Specifically, derivatives 4b and 4g exhibited potent cytotoxicity, with IC(50) values of 15 +/- 1.24 muM and 16 +/- 1.54 muM, respectively, demonstrating marked improvement over the parent compound, which displayed an IC(50) of 65 +/- 4.62 muM, against fibrosarcoma cells (HT1080). Mechanistic studies revealed that compounds 4b and 4g induced cell cycle arrest at the G2/M phase, as determined by flow cytometry. Furthermore, molecular docking analyses targeting the CDK1-Cyclin B complex, a key regulator of mitosis, supported the observed biological activities and provided insight into potential binding interactions.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.